Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | MAOA | P21397 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | ESR1 | P03372 | 1/20 | 0.30 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.30 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4466718 | 1.00 | SMN1; SMN2 (0.35) | SMN1; SMN2LMNATP53RAB9AMAOA | |
| SCHEMBL4478457 | 0.92 | POLB (0.39) | SMN1; SMN2TP53RAB9APOLBNPSR1 | |
| SCHEMBL4478451 | 0.92 | POLB (0.39) | SMN1; SMN2TP53RAB9APOLBNPSR1 | |
| SCHEMBL4491288 | 0.88 | POLB (0.38) | SMN1; SMN2LMNARAB9ACYP1A2CYP3A4 | |
| SCHEMBL4491294 | 0.88 | POLB (0.38) | SMN1; SMN2LMNARAB9ACYP1A2CYP3A4 | |
| SCHEMBL4469610 | 0.84 | CYP1A2 (0.36) | SMN1; SMN2RAB9ACYP1A2CYP3A4CYP2C19 | |
| SCHEMBL4469607 | 0.84 | CYP1A2 (0.36) | SMN1; SMN2RAB9ACYP1A2CYP3A4CYP2C19 | |
| SCHEMBL4473544 | 0.82 | CYP1A2 (0.36) | SMN1; SMN2LMNATP53RAB9ACYP1A2 | |
| SCHEMBL4475755 | 0.81 | SMN1; SMN2 (0.39) | SMN1; SMN2LMNARAB9ACYP1A2CYP3A4 | |
| SCHEMBL4475763 | 0.81 | SMN1; SMN2 (0.39) | SMN1; SMN2LMNARAB9ACYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7582651-B2 | Pyrrolopyridine derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-09-01 | — | — | US | disclosed |
| US-20060167038-A1 | Pyrrolopyridine derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-07-27 | — | — | US | disclosed |
| EP-1535922-A1 | PYRROLOPYRIDINE DERIVATIVE AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2005-06-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060167038-A1 | Pyrrolopyridine derivative and use thereof | OPRD1, TRPV1, OPRM1 | SMN1; SMN2 3351/4885LMNA 4879/4885TP53 4488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.